Anti-Obesity Drug Discovery and Development

Anti-Obesity Drug Discovery and Development

Volume: 3

Obesity is a complex health problem, caused by a number of factors such as excessive food intake, lack of physical activity, genetic predisposition, endocrine disorders, medications and psychiatric ...
[view complete introduction]

US $

*(Excluding Mailing and Handling)

Proteomics in the Characterization of New Target Therapies in Pediatric Obesity Treatment

Pp. 80-148 (69)

Gillian E. Walker, Marilisa De Feudis, Marta Roccio, Gianni Bona and Flavia Prodam


Adipose tissue (AT) with a central role in body weight homeostasis, inflammation and insulin resistance, is a highly orchestrated tissue involving receptor and second messenger pathways with steps and passes that influence hyperplasia, hypertrophy, adipocyte differentiation, turnover, lipolysis, free-fatty acid (FFA) metabolism, lipogenesis and the secretome profile. Due to the limitations of the classical molecular biological methods only pieces of the puzzle have been studied, with studies failing to consider the global, time-resolved changes that are evident in this highly plastic organ. “Proteomics”, first coined in 1995 is a large-scale characterization of the entire protein profile of a cell line, tissue, or organism not only from the perspective of expression but also post-translational modifications. As such proteomic technologies offer powerful tools for identifying key components of the adipose proteome, which may contribute to the pathogenesis of adipose tissue dysfunction in obesity. In this review, we plan to address the recent advances in the proteomic characterization of pediatric obesity, in particular the newly identified proteins that potentially play relevant roles and offer targets for novel therapies.


Adipose tissue, Biomarkers, Circulation, Lifestyle, Obesity, Pediatric, Proteomic, Secretome, Therapy.


Laboratory of Clinical Pediatrics, Department of Health Sciences, Università Del Piemonte Orientale, Novara, Italy.